Can-Fite BioPharma American Depositary Shares
CANF
8 hedge funds and large institutions have $1.06M invested in Can-Fite BioPharma American Depositary Shares in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.
98% more capital invested
Capital invested by funds: $536K → $1.06M (+$524K)
3.87% more ownership
Funds ownership: 4.03% → 7.9% (+3.9%)
11% less funds holding
Funds holding: 9 → 8 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$477K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$29.6K |
| 3 |
Morgan Stanley
New York
|
+$19.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIA
Schechter Investment Advisors
Birmingham,
Michigan
|
-$44.2K |
| 2 |
SHIM
Stone House Investment Management
Tunkhannock,
Pennsylvania
|
-$1.03K |
| 3 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$54 |
CANF Hedge Fund Activity: Q1 2024 in Review
8 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2024, worth a combined $1.06M — up 98% from $536K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CANF and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Armistice Capital, adding an estimated $477K. The largest seller was Schechter Investment Advisors, exiting entirely with an estimated $44.2K sold.
- 8 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2024, down from 9 in Q4 2023.
- Funds reported $1.06M of Can-Fite BioPharma American Depositary Shares stock for Q1 2024, up 98% quarter-over-quarter.
- 2 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2024 was Armistice Capital, an estimated $477K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2024 was Schechter Investment Advisors, an estimated $44.2K sold.
Based on aggregated 13F filings for Q1 2024.